Skip to main content
Erschienen in: Journal of Genetic Counseling 5/2009

01.10.2009 | Original Research

Telephoned BRCA1/2 Genetic Test Results: Prevalence, Practice, and Patient Satisfaction

verfasst von: L. Baumanis, J. P. Evans, N. Callanan, L. R. Susswein

Erschienen in: Journal of Genetic Counseling | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

While the traditional model of genetic evaluation for breast cancer risk recommended face-to-face disclosure of genetic testing results, BRCA1/2 testing results are increasingly provided by telephone. The few existing studies on telephone genetic counseling provide conflicting results about its desirability and efficacy. The current study aimed to (1) Estimate the prevalence among genetic counselors of providing BRCA1/2 genetic test results by phone (2) Assess patient satisfaction with results delivered by telephone versus in-person. A survey was sent to members of the Familial Cancer Risk Counseling Special Interest Group via the NSGC listserve and was completed by 107 individuals. Additionally, 137 patients who had received BRCA genetic testing results either by phone or in-person at UNC Chapel Hill Cancer Genetics Clinic were surveyed regarding satisfaction with the mode of their BRCA1/2 results delivery. The genetic counseling survey revealed that the majority of responding counselors (92.5%) had delivered BRCA1/2 genetic test results by telephone. Patients having received results either in person or by phone reported no difference in satisfaction. Most patients chose to receive results by phone and those given a choice of delivery mode reported significantly higher satisfaction than those who did not have a choice. Those who waited less time to receive results once they knew they were ready also reported higher satisfaction. This study found supportive results for the routine provision of BRCA1/2 genetic test results by telephone. Results suggest that test results should be delivered as swiftly as possible once available and that offering patients a choice of how to receive results is desirable. These are especially important issues as genetic testing becomes more commonplace in medicine.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat American College of Medical Genetics Foundation. (1999). Genetic susceptibility to breast and ovarian cancer: Assessment, counseling and testing guidelines. New York: American College of Medical Genetics Foundation. American College of Medical Genetics Foundation. (1999). Genetic susceptibility to breast and ovarian cancer: Assessment, counseling and testing guidelines. New York: American College of Medical Genetics Foundation.
Zurück zum Zitat Baker, D. L., Schuette, J. L., & Uhlmann, W. R. (eds). (1998). A guide to genetic counseling. New York: Wiley. Baker, D. L., Schuette, J. L., & Uhlmann, W. R. (eds). (1998). A guide to genetic counseling. New York: Wiley.
Zurück zum Zitat International Huntington Association and World Federation of Neurological Research Group on Huntington’s Chorea. (1994). Guidelines for the molecular genetics predictive test in Huntington’s disease. Neurology, 44, 1533–1536. International Huntington Association and World Federation of Neurological Research Group on Huntington’s Chorea. (1994). Guidelines for the molecular genetics predictive test in Huntington’s disease. Neurology, 44, 1533–1536.
Zurück zum Zitat Jenkins, J., Calzone, K. A., Dimond, E., Liewehr, D. J., Steinberg, S. M., Jourkiv, O., et al. (2007). Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling. Genetics in Medicine, 9(8), 487–495. doi:10.1097/GIM.0b013e31812e6220.PubMedCrossRef Jenkins, J., Calzone, K. A., Dimond, E., Liewehr, D. J., Steinberg, S. M., Jourkiv, O., et al. (2007). Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling. Genetics in Medicine, 9(8), 487–495. doi:10.​1097/​GIM.​0b013e31812e6220​.PubMedCrossRef
Zurück zum Zitat Klemp, J. R., O’Dea, A., Chamberlain, C., & Fabian, C. J. (2005). Patient satisfaction of BRCA1/2 genetic testing by women at high risk for breast cancer participating in a prevention trial. Familial Cancer, 4, 279–284. doi:10.1007/s10689-005-1474-y.PubMedCrossRef Klemp, J. R., O’Dea, A., Chamberlain, C., & Fabian, C. J. (2005). Patient satisfaction of BRCA1/2 genetic testing by women at high risk for breast cancer participating in a prevention trial. Familial Cancer, 4, 279–284. doi:10.​1007/​s10689-005-1474-y.PubMedCrossRef
Zurück zum Zitat Ormond, K. E., Haun, J., Cook, L., Duguette, D., Ludowese, C., & Matthews, A. L. (2000). Recommendations for telephone counseling. Journal of Genetic Counseling, 9(1), 63–71. doi:10.1023/A:1009433224504.CrossRef Ormond, K. E., Haun, J., Cook, L., Duguette, D., Ludowese, C., & Matthews, A. L. (2000). Recommendations for telephone counseling. Journal of Genetic Counseling, 9(1), 63–71. doi:10.​1023/​A:​1009433224504.CrossRef
Zurück zum Zitat Peshkin, B. N., DeMarco, T. A., Graves, K. D., Brown, K., Nusbaum, R. H., Moglia, D., et al. (2008). Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial. Genetic Testing, 12(1), 37–52. doi:10.1089/gte.2006.0525.PubMedCrossRef Peshkin, B. N., DeMarco, T. A., Graves, K. D., Brown, K., Nusbaum, R. H., Moglia, D., et al. (2008). Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial. Genetic Testing, 12(1), 37–52. doi:10.​1089/​gte.​2006.​0525.PubMedCrossRef
Zurück zum Zitat Petrucelli, N., Daly, M. B., Culver, J. O., Levy-Lahad, E., & Feldman, G. L. (2005). BRCA1 and BRCA2 hereditary breast/ovarian cancer. Retrieved April, 2, 2006, from http://www.genereviews.org. Petrucelli, N., Daly, M. B., Culver, J. O., Levy-Lahad, E., & Feldman, G. L. (2005). BRCA1 and BRCA2 hereditary breast/ovarian cancer. Retrieved April, 2, 2006, from http://​www.​genereviews.​org.
Zurück zum Zitat Schneider, K. (2002). Counseling about cancer: Strategies for genetic counseling (2nd ed.). New York: Wiley. Schneider, K. (2002). Counseling about cancer: Strategies for genetic counseling (2nd ed.). New York: Wiley.
Zurück zum Zitat Young, T. (1993). Issues in quality assurance explored: is telephone counseling an oxymorom? Perspectives in Genetic Counseling, 15(2), 2–3. Young, T. (1993). Issues in quality assurance explored: is telephone counseling an oxymorom? Perspectives in Genetic Counseling, 15(2), 2–3.
Metadaten
Titel
Telephoned BRCA1/2 Genetic Test Results: Prevalence, Practice, and Patient Satisfaction
verfasst von
L. Baumanis
J. P. Evans
N. Callanan
L. R. Susswein
Publikationsdatum
01.10.2009
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling / Ausgabe 5/2009
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-009-9238-8

Weitere Artikel der Ausgabe 5/2009

Journal of Genetic Counseling 5/2009 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.